Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling-Reference-Cited by-同舟云学术

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

Published:2019-08-07 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

De Sousa Linhares Annika,Battin Claire,Jutz Sabrina,Leitner Judith,Hafner Christine,Tobias Joshua^ORCID,Wiedermann Ursula^ORCID,Kundi Michael^ORCID,Zlabinger Gerhard J.^ORCID,Grabmeier-Pfistershammer Katharina^ORCID,Steinberger Peter^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-47910-1.pdf

Reference33 articles.

1. Gong, J., Chehrazi-Raffle, A., Reddi, S. & Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6, 8, https://doi.org/10.1186/s40425-018-0316-z (2018).

2. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 8, https://doi.org/10.1126/scitranslmed.aad7118 (2016).

3. Jutz, S. et al. A cellular platform for the evaluation of immune checkpoint molecules. Oncotarget 8, 64892–64906, https://doi.org/10.18632/oncotarget.17615 (2017).

4. Leitner, J. et al. T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. J Immunol Methods 362, 131–141 (2010).

5. Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423–1427 (2017).

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Efficacy and Safety of Durvalumab Rechallenge in Advanced Hepatocellular Carcinoma Patients Refractory to Prior Anti-PD-1 Therapy;2024-08-09

3. Glycosylation: mechanisms, biological functions and clinical implications;Signal Transduction and Targeted Therapy;2024-08-05

4. NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody;Molecular Therapy;2024-08

5. BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes;iScience;2024-07